WHICH IS THE OPTIMAL ANTIOBESITY AGENT FOR PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

Descargar Publicación
Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity Beber té negro podría reducir el riesgo de mortalidad, sugiere un estudio